<DOC>
	<DOCNO>NCT00139893</DOCNO>
	<brief_summary>To determine whether new Orally Disintegrating Tablet Reglan ( metoclopramide ) metabolize faster conventional Reglan tablet patient diabetic gastroparesis , pharmacokinetics follow single 10 mg dose formulation compare . Subjects must 18 old , Type 1 2 diabetes document gastroparesis agree withhold medication gastroparesis 3 day prior dose . Exclusion criterion include serum glucose &gt; 300 mg/dL , Hb1Ac &gt; 10 % , concurrent illness interfere gastrointestinal motility . Subjects stay clinic overnight , pharmacokinetic sampling continue 8 hour first morning dose . The time ( Tmax ) amount ( Cmax ) peak concentration area curve ( AUC ) time zero 8 hr compare 2 formulation .</brief_summary>
	<brief_title>A Randomized , Open-label , Two-way Crossover Trial Determine Pharmacokinetics Metoclopramide When Administered Orally Disintegrating Tablet Compared ReglanÂ® Tablets Subjects With Diabetic Gastroparesis</brief_title>
	<detailed_description>See approve Package Insert Adverse Event information .</detailed_description>
	<mesh_term>Gastroparesis</mesh_term>
	<mesh_term>Metoclopramide</mesh_term>
	<criteria>Subjects must 18 old , Type 1 2 diabetes document gastroparesis Serum glucose &gt; 300 mg/dL , HbA1C &gt; 10 % , concurrent illness interfere gastrointestinal motility</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2008</verification_date>
</DOC>